

VEQ 360°



Una risorsa indispensabile per confermare e migliorare la qualità di tutto il tuo laboratorio.

Catalogo 2026

LABQUALITY

Microbiologia e Virologia



Microbiology

The microbiological EQA programs are suitable for clinical laboratories and POCT sites performing testing in the areas of bacterial serology, bacteriology, mycology, parasitology and virology. While the selection includes schemes for antigen detection, antibody detection, culture, microscopy, and PCR tests, solutions for versatile needs are available. Authentic single donor samples are included in multiple schemes.

Microbiology » Bacterial Serology

5840 <i>Antistreptolysin</i>	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 2 plasma or serum samples, 0.4 mL. Examinations: Qualitative and quantitative ASO.	
5950 <i>Bordetella pertussis</i> , antibodies	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 2 plasma or serum samples, 0.3 mL. Examinations: <i>B. pertussis</i> IgA, IgG & IgM antibodies, Pertussis toxin IgA, IgG & IgM, post-analytical clinical interpretation.	EQA ³
5960 <i>Borrelia burgdorferi</i> , antibodies, European origin	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 2 plasma or serum samples, 0.5 mL. Examinations: <i>B. burgdorferi</i> IgG, IgM and total antibodies, post-analytical clinical interpretation.	EQA ³
5850 <i>Brucella</i> antibodies	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 2 plasma or serum samples, 0.5 mL. Examinations: <i>Brucella</i> IgG, IgM and total antibodies.	
5965 CXCL 13 Chemokine	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 2 liquid samples. Examinations: Chemokine CXCL13 detection.	
5620 <i>Chlamydia pneumoniae</i> , antibodies	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 2 plasma or serum samples, 0.4 mL. Examinations: <i>C. pneumoniae</i> IgA, IgG, IgM antibodies, post-analytical clinical interpretation.	EQA ³
5851 <i>Francisella tularensis</i> , antibodies	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 3 plasma or serum samples, 0.5 mL. Examinations: <i>Francisella tularensis</i> IgG, IgM and total antibodies.	
5860 <i>Helicobacter pylori</i> , antibodies	3	<div>1 2 3 4 5 6 7 8 9 10 11 12</div> <div>• • • • •</div>	Specimens: 2 plasma or serum samples, 0.4 mL. Examinations: <i>H. pylori</i> IgA, IgG and total antibodies, quantitative and qualitative tests, post-analytical clinical interpretation.	POCT EQA ³

EQA ³	5980	<i>Mycoplasma pneumoniae</i> , antibodies	3	1	2	3	4	5	6	7	8	9	10	11	12
					•			•				•		•	
POCT				Specimens: 2 plasma or serum samples, 0.3 mL. Authentic, single donor samples. Examinations: <i>M. pneumoniae</i> IgG, IgM and total antibodies, post-analytical clinical interpretation.											
				Notes: For clinical laboratories and POCT sites.											

EQA ³	5880	Syphilis serology	3	1	2	3	4	5	6	7	8	9	10	11	12
					•				•				•		•
				Specimens: 2 serum samples, 0.6 mL.											
				Examinations: Cardiolipin, <i>Treponema pallidum</i> antibodies, post-analytical clinical interpretation.											

Microbiology » Bacteriology

5050	Bacteriological staining, direct	3	1	2	3	4	5	6	7	8	9	10	11	12
						•						•		
			Specimens: 3 cases, 3–9 digital images.			Examinations: Interpretation of digital images taken from the direct bacteriological Gram staining of clinical samples.								

5100 Blood culture (incl. sepsis multiplex methods)			1	2	3	4	5	6	7	8	9	10	11	12
					●		●					●		●
Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation. The samples intended for susceptibility testing may include both international quality control strains and clinical strains.			Examinations: Culture, identification, antimicrobial susceptibility testing. Direct nucleic acid detection from positive blood culture bottles by multiplex methods is included in the scheme.											
			Notes: Fresh blood is needed but not included in the shipment.											

5101	Blood culture, screening (incl. sepsis multiplex methods)	1	1	2	3	4	5	6	7	8	9	10	11	12	
					•		•					•		•	
			Specimens: 3 lyophilised samples. Brief case histories also given. Fresh blood is needed in the specimen preparation.			Notes: Fresh blood is needed but not included in the shipment.									
			Examinations: Culture, preliminary identification using Gram staining and/or direct nucleic acid detection from positive blood culture bottles by multiplex methods. The scheme is also suitable for stem cell banks screening only for possible growth.												

NEW	5241	<i>Bordetella pertussis/parapertussis</i> , nucleic acid detection	1	1	2	3	4	5	6	7	8	9	10	11	12
								●					●		
Specimens: 2 artificial samples, 1 mL.				Examinations: Detection of <i>B. pertussis</i> and <i>B. parapertussis</i> nucleic acid.											

5150	Cerebrospinal fluid, bacterial culture	1	1	2	3	4	5	6	7	8	9	10	11	12			
				●			●				●			●			
			Specimens: 2 lyophilised samples. Brief case histories are also given.			Notes: See also scheme 5303 Meningitis-encephalitis multiplex, nucleic acid detection.											
			Examinations: Culture and identification. The scheme is also suitable for laboratories performing screening and reporting merely a preliminary identification.														

5612	Chlamydia trachomatis and Neisseria gonorrhoeae, nucleic acid detection	3	1	2	3	4	5	6	7	8	9	10	11	12
					•		•			•			•	
			Specimens: 3 simulated swab/urine samples, 2 mL.											
			Examinations: Detection of <i>C. trachomatis</i> and <i>N. gonorrhoeae</i> nucleic acid.											
			Notes: See also scheme 5302 Sexually transmitted diseases multiplex, nucleic acid detection. The samples contain hDNA.											

5200	<i>Clostridioides difficile</i> , culture and toxin detection	1	1	2	3	4	5	6	7	8	9	10	11	12
				●			●			●			●	
			Specimens: 2 lyophilised mixtures of bacteria.			Examinations: This scheme includes <i>C. difficile</i> culture, antigen detection (GDH), toxin detection and direct nucleic acid detection. Hypervirulent <i>C. difficile</i> strains also included.								

5202 <i>Clostridioides difficile</i> , extra set of samples		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 2 lyophilised mixtures of bacteria.		Notes: Only in connection with scheme 5200.											

5201 <i>Clostridioides difficile</i> , nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 2 lyophilised mixtures of bacteria.		Notes: 5200 includes also this examination.											
Examinations: <i>C. difficile</i> direct nucleic acid detection. Hypervirulent <i>C.difficile</i> strains also included.													

5191 Faecal bacterial pathogens multiplex, nucleic acid detection		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 3 samples. Either lyophilised mixtures of bacteria and/or simulated samples, 1 mL.		Notes: During the period of one calendar year, a comprehensive selection of listed pathogens will be covered.											
Examinations: Direct nucleic acid detection. Pathogens included are <i>Aeromonas</i> , <i>Campylobacter</i> , <i>C. difficile</i> , <i>E. coli</i> EHEC (stx1/stx2), <i>E. coli</i> EAEC, <i>E. coli</i> EIEC, <i>E. coli</i> EPEC, <i>E. coli</i> ETEC, <i>Plesiomonas</i> , <i>Salmonella</i> , <i>Shigella</i> , <i>Vibrio</i> and <i>Yersinia</i> .													

5190 Faecal culture		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 2 lyophilised mixtures of bacteria.		Examinations: Culture, identification and antimicrobial susceptibility (rounds 2 and 4). In addition to culture, samples are also suitable for direct nucleic acid detection. Pathogens included are <i>Aeromonas</i> , <i>Campylobacter</i> , <i>Plesiomonas</i> , <i>Salmonella</i> , <i>Shigella</i> and <i>Yersinia</i> .											

5080 General Bacteriology 1 (aerobes and anaerobes)		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 4 lyophilised mixtures of microbes: both pathogens and normal flora. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.		Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases.											
		Notes: 5080 includes 5081, General Bacteriology 2.											

5081 General Bacteriology 2 (aerobes)		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 2 lyophilised mixtures of microbes: both pathogens and normal flora. The specimens intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Brief case histories are also given. Pre- and/or post-analytical cases in part of the rounds.		Examinations: Isolation of pathogens and antimicrobial susceptibility testing, pre- and/or post-analytical cases.											
		Notes: 5080 General Bacteriology 1 includes 5081.											

5041 Gram stain, blood culture		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 2 air-dried, unfixed microbe suspensions on slides. Brief case histories also given.		Examinations: Staining and microscopy.											

5040 Gram stain, colonies		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 3 air-dried, unfixed microbe suspensions on a slide.		Examinations: Staining and microscopy.											

5043 Gram stain, vaginal fluid		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: Digital images of three Gram-stained vaginal fluid samples with brief case histories.		Examinations: Evaluation of Gram-stained vaginal fluid.											

5596 <i>Helicobacter pylori</i> , antigen detection in faeces		1	2	3	4	5	6	7	8	9	10	11	12
Specimens: 3 lyophilised faecal samples.		Examinations: <i>H. pylori</i> antigen detection.											
		Notes: For clinical laboratories and POCT sites.											

	1	2	3	4	5	6	7	8	9	10	11	12
5253 <i>Helicobacter pylori</i> , drug resistance, nucleic acid detection			●						●			
Specimens: 3 simulated swab samples.	Examinations: <i>H. pylori</i> nucleic acid detection, clarithromycin susceptibility.											

	1	2	3	4	5	6	7	8	9	10	11	12
5597 <i>Legionella</i> , antigen detection in urine			●		●				●			●
Specimens: 3 simulated urine samples.	Examinations: <i>Legionella</i> antigen detection.											

	1	2	3	4	5	6	7	8	9	10	11	12
5230 <i>Mycobacterium tuberculosis</i> , drug resistance, nucleic acid detection			●			●			●			●
Specimens: 2 simulated samples, 1 mL.	Examinations: <i>Mycobacterium tuberculosis</i> nucleic acid detection, rifampicin susceptibility and isoniazid susceptibility.											

	1	2	3	4	5	6	7	8	9	10	11	12
5231 <i>Mycobacterium tuberculosis</i> , drug resistance, nucleic acid detection, extra set of samples			●			●			●			●
Specimens: 2 simulated samples, 1 mL.	Notes: Only in connection with scheme 5230.											

	1	2	3	4	5	6	7	8	9	10	11	12
5220 <i>Mycobacterial</i> culture and stain			●			●			●			●
Specimens: 2 lyophilised samples and 2 fixed smears on slides. Examinations: Detection of <i>Mycobacterium tuberculosis</i> , <i>Mycobacterium tuberculosis</i> complex and atypical mycobacteria: culture, direct nucleic acid detection, acid-fast staining and microscopy.	Notes: See also products 5250 and 5251 IGRA for <i>M. tuberculosis</i> .											

	1	2	3	4	5	6	7	8	9	10	11	12
5221 <i>Mycobacterial</i> nucleic acid detection			●			●			●			●
Specimens: 2 lyophilised samples. Examinations: Direct nucleic acid detection.	Notes: 5220 includes also his examination. For additional set of samples, order scheme 5222.											

	1	2	3	4	5	6	7	8	9	10	11	12
5222 <i>Mycobacteria</i> , extra set of samples			●			●			●			●
Specimens: 2 lyophilised samples.	Notes: Only in connection with scheme 5220 or 5221.											

	1	2	3	4	5	6	7	8	9	10	11	12
5240 <i>Mycobacterial</i> stain			●			●			●			●
Specimens: 2 fixed smears on slides.	Examinations: Acid-fast staining and microscopy.											

	1	2	3	4	5	6	7	8	9	10	11	12
5254 <i>Mycoplasma genitalium</i> , drug resistance, nucleic acid detection		●			●			●			●	
Specimens: 3 simulated swab samples. Examinations: <i>M. genitalium</i> nucleic acid detection, macrolide (azithromycin) susceptibility. Some rounds will include a fluoroquinolone (moxifloxacin) resistant sample.	Notes: The samples contain hDNA.											

	1	2	3	4	5	6	7	8	9	10	11	12
5120 <i>Neisseria gonorrhoeae</i> (Gc), culture and susceptibility testing			●		●			●			●	
Specimens: 2 lyophilised mixtures of microbes. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains.	Examinations: Culture, identification and antimicrobial susceptibility testing. Also suitable for laboratories performing preliminary screening.											

5180	Salmonella, culture	1	1	2	3	4	5	6	7	8	9	10	11	12
						•		•				•		•
Specimens: 2 lyophilised mixtures of bacteria.			Notes: 5190 also includes 5180.											
Examinations: Culture.														

5594	Streptococcus agalactiae (GBS), culture	1	1	2	3	4	5	6	7	8	9	10	11	12
						•		•				•		•
Specimens: 2 lyophilised samples. Samples include pathogens and/or normal flora.			Notes: See also product 5599 for direct <i>S. agalactiae</i> nucleic acid detection from sample.											
Examinations: Culture.														

5599	Streptococcus agalactiae (GBS), nucleic acid detection	3	1	2	3	4	5	6	7	8	9	10	11	12
						•		•				•		•
Specimens: 2 swab samples. Samples also include normal flora.			Notes: The samples contain hDNA. See also product 5594 for <i>S. agalactiae</i> (GBS) culture.											
Examinations: Direct nucleic acid detection.														

5598	Streptococcus pneumoniae, antigen detection in urine	3	1	2	3	4	5	6	7	8	9	10	11	12
					•		•					•		
Specimens: 3 simulated urine specimens.			Examinations: <i>S. pneumoniae</i> antigen detection.											

5595	Streptococcus pyogenes (Group A), detection in pharyngeal sample	3	1	2	3	4	5	6	7	8	9	10	11	12
					•		•					•		
Specimens: 3 simulated pharyngeal samples.			Notes: For clinical laboratories and POCT sites.											
Examinations: Strep A Ag, Strep A NAT.														

5073	Surveillance for multidrug resistant bacteria, gramnegative rods	1	1	2	3	4	5	6	7	8	9	10	11	12
				•				•				•		•
Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.			Examinations: The scheme is intended for laboratories performing screening of multidrug resistant gramnegative rods (e.g. CPE, ESBL, MDR <i>Acinetobacter</i> and <i>P. aeruginosa</i>) by culture and/or direct nucleic acid detection method.											

5071	Surveillance for multidrug resistant bacteria, MRSA	1	1	2	3	4	5	6	7	8	9	10	11	12
				•				•				•		•
Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.			Examinations: The scheme is intended for laboratories performing screening of MRSA (methicillin resistant <i>Staphylococcus aureus</i>) by culture and/or direct nucleic acid detection method.											

5072	Surveillance for multidrug resistant bacteria, VRE	1	1	2	3	4	5	6	7	8	9	10	11	12
				•				•				•		•
Specimens: 1 lyophilised mixture of microbes; including pathogens and/or normal flora.			Examinations: The scheme is intended for laboratories performing screening of VRE (vancomycin-resistant enterococci) by culture and/or direct nucleic acid detection method.											

5140	Throat streptococcal culture	1	1	2	3	4	5	6	7	8	9	10	11	12
					•		•				•			•
Specimens: 3 lyophilised mixtures of bacteria.			Examinations: Culture and identification of group A, C and G streptococci.											

		1	2	3	4	5	6	7	8	9	10	11	12
EQA³	5060 Urine culture, quantitative screening	1		•			•			•			•
	Specimens: 2 lyophilised samples and dilutor. Brief case histories also given. Pre- and/or post-analytical cases in part of the rounds. Examinations: Culture and quantitation, pre-and/or post-analytical indicators.		Notes: Scheme 3170 available for urine bacterial screening with automated analysers.										

		1	2	3	4	5	6	7	8	9	10	11	12
EQA³	5065 Urine culture, quantitative screening, identification and susceptibility	1		•			•			•			•
	Specimens: 2 lyophilised samples and dilutor. Brief case histories also given. The samples intended for susceptibility testing may include both international quality control strains and susceptible or resistant clinical strains. Pre- and/or post-analytical cases in part of the rounds. Examinations: Culture, quantitation, identification and antimicrobial susceptibility testing, pre-and/or post-analytical indicators. Notes: Scheme 3170 available for urine bacterial screening with automated analysers.												

Microbiology » Mycology

		1	2	3	4	5	6	7	8	9	10	11	12
5260 Fungal culture	1			•		•				•		•	
Specimens: 3 lyophilised samples. Brief case histories also given. The samples may include moulds, dermatophytes and yeasts.	Examinations: Culture and identification. Antimicrobial susceptibility testing of yeast strains.												

		1	2	3	4	5	6	7	8	9	10	11	12
5261 Fungal infections, nucleic acid detection	1				•					•			
Specimens: 3-4 simulated samples. The samples may include yeasts, dermatophytes and moulds. Examinations: Nucleic acid detection according to laboratory's own test selection.	Notes: Test selection of the participating lab is taken into consideration in result processing. The samples contain hDNA.												

Microbiology » Parasitology

		1	2	3	4	5	6	7	8	9	10	11	12
5472 Faecal parasites multiplex, nucleic acid detection	1		•			•			•			•	
Specimens: 3 lyophilised samples.	Examinations: Nucleic acid detection of <i>Cryptosporidium</i> , <i>Dientamoeba fragilis</i> , <i>Entamoeba histolytica</i> and <i>Giardia lamblia</i> .												

POCT		1	2	3	4	5	6	7	8	9	10	11	12
5430 Malaria, antigen and nucleic acid detection	3		•			•			•			•	
Specimens: 3 whole blood samples. The scheme contains primarily <i>Plasmodium falciparum</i> positive and negative samples, occasionally other <i>Plasmodium</i> species are included.	Examinations: Antigen and nucleic acid detection. Target antigens: HRP2 and/or pLDH and/or aldolase. Notes: For clinical laboratories and POCT sites.												

		1	2	3	4	5	6	7	8	9	10	11	12
5462 Malaria screening, Giemsa stain	3		•			•			•			•	
Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.	Examinations: Preliminary screening of malaria plasmodia.												

		1	2	3	4	5	6	7	8	9	10	11	12
5463 Malaria screening, MGG stain	3		•			•			•			•	
Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.	Examinations: Preliminary screening of malaria plasmodia.												

		1	2	3	4	5	6	7	8	9	10	11	12
5460 Parasites in blood, Giemsa stain	3		•			•			•			•	
Specimens: 2 methanol fixed or Giemsa stained smears. Brief case histories also given.	Examinations: Screening and identification of malaria plasmodia and other blood parasites.												

	1	2	3	4	5	6	7	8	9	10	11	12
5461 Parasites in blood, MGG stain		•			•			•			•	
Specimens: 2 methanol fixed or May-Grünwald-Giemsa stained smears. Brief case histories are also given.	Examinations: Screening and identification of malaria plasmodia and other blood parasites.											

	1	2	3	4	5	6	7	8	9	10	11	12
5440 Parasites in faeces		•			•			•			•	
Specimens: 3 stool samples in formalin. Brief case histories also given.	Examinations: Screening and identification of intestinal parasites (ova and parasites).											

	1	2	3	4	5	6	7	8	9	10	11	12
5450 Parasites in faeces, virtual microscopy				•						•		
Specimens: Virtual whole slide images of stool samples in formalin prepared by using a scanner microscope. Brief case histories also given.	Examinations: Screening and identification of intestinal parasites (ova and parasites).											

	1	2	3	4	5	6	7	8	9	10	11	12
5420 Toxoplasma, antibodies		•			•			•			•	
Specimens: 3 plasma samples, 0.7 mL. Authentic, single donor samples. Brief case histories also given.	Examinations: Toxoplasma IgG, IgM and total antibodies, IgG avidity, postanalytical clinical interpretation.											

EQA³

	1	2	3	4	5	6	7	8	9	10	11	12
5473 Trichomonas vaginalis, detection		•		•				•		•		
Specimens: 2 simulated samples. Examinations: Detection of Trichomonas vaginalis antigen and nucleic acid (NAT).	Notes: The samples contain hDNA.											

POCT

Microbiology » Virology

	1	2	3	4	5	6	7	8	9	10	11	12
5651 CMV and EBV, nucleic acid detection, quantitative			•							•		
Specimens: 5 samples simulating plasma, 1.5 mL. Examinations: CMV and EBV NAT (quantitative).	Notes: Quantitative result processing.											

	1	2	3	4	5	6	7	8	9	10	11	12
5650 Cytomegalovirus, antibodies		•			•				•			•
Specimens: 3 plasma samples, 0.7 mL.	Examinations: Cytomegalovirus IgG, IgM and total antibodies, IgG avidity and post-analytical clinical interpretation.											

EQA³

	1	2	3	4	5	6	7	8	9	10	11	12
5635 Dengue virus, antibodies and antigen detection			•			•			•		•	
Specimens: 3 plasma or serum samples, 0.5 mL.	Examinations: Dengue virus IgG and IgM antibodies, Dengue virus antigen (NS1) and post-analytical clinical interpretation.											

EQA³ POCT

	1	2	3	4	5	6	7	8	9	10	11	12
5640 EBV mononucleosis, POCT		•			•				•			•
Specimens: 3 plasma samples, 0.5 mL. Examinations: MonAb.	Notes: For clinical laboratories and POCT sites.											

POCT

	1	2	3	4	5	6	7	8	9	10	11	12
5641 EBV mononucleosis, specific antibodies		•			•				•			•
Specimens: 3 plasma samples, 1.4 mL.	Examinations: EBNA AbG, EBV VCA AbG, EBV VCA AbM, IgG Avidity and post-analytical clinical interpretation.											

EQA³

POCT	5687 HBsAg and HCVAb POCT	3	1	2	3	4	5	6	7	8	9	10	11	12			
				●			●			●			●				
			Specimens: 3 plasma or serum samples, 0.5 mL.			Notes: This scheme is only for POC tests. Scheme 5094-5096 is for clinical laboratories.											
			Examinations: HBsAg, HCVAb POCT.														

POCT NEW	5689 HCV RNA from capillary blood, POCT	3	1	2	3	4	5	6	7	8	9	10	11	12			
							●					●					
			Specimens: To be announced.			Examinations: HCV NAT (RNA).											

EQA ³	5092 Hepatitis A, antibodies	3	1	2	3	4	5	6	7	8	9	10	11	12			
				●			●			●			●				
			Specimens: 3 plasma or serum samples, 0.6 mL.			Examinations: HAVAb, HAVAbM, HAVAbG and post-analytical clinical interpretation.											

EQA ³	5094–5096 Hepatitis B and C, serology, specimen volume 0.6 mL / 1.2 mL / 2.0 mL	3	1	2	3	4	5	6	7	8	9	10	11	12
				•			•			•			•	
			Volume-specific product codes:											
			5094: 0.6 mL											
			5095: 1.2 mL											
			5096: 2.0 mL											
			Notes: For clinical laboratories. Scheme 5687 is for POCT users.											
Specimens: 3 plasma or serum samples, 0.6 / 1.2 / 2 mL. Choose the sample volume according to your test selection.														
Examinations: HBsAg, HBsAgCt, HBcAb, HBcAbM, HBeAb, HBeAg, HBsAb (qual), HCVAb, HCVAbCt, and post-analytical clinical interpretation.														

5093 Hepatitis B, s-antigen antibodies, quantitative	3	1	2	3	4	5	6	7	8	9	10	11	12	
		●			●			●			●			
Specimens: 2 plasma or serum samples, 0.5 mL. Authentic, single donor samples.		Examinations: HBsAb (anti-HBs), quantitative.												

5679 Hepatitis B virus, nucleic acid detection (DNA)	3	1	2	3	4	5	6	7	8	9	10	11	12
				•		•				•		•	
Specimens: 3 lyophilised plasma samples, 1,5 mL.		Examinations: HBV DNA, quantitative and/or qualitative nucleic acid detection.											

5678 Hepatitis C virus, nucleic acid detection (RNA)	3	1	2	3	4	5	6	7	8	9	10	11	12
				●		●				●		●	
Specimens: 3 lyophilised plasma samples, 1.1 mL.		Examinations: HCV RNA, quantitative and/or qualitative nucleic acid detection.											

EQA ³	5682 Hepatitis E, antibodies	3	1	2	3	4	5	6	7	8	9	10	11	12	
						●						●			
			Specimens: 3 plasma or serum samples, 0.5 mL.			Examinations: HEV Ab, HEV IgG, HEV IgM, post-analytical clinical interpretation.									

5555 Herpes simplex 1 and 2, antibodies	3	1	2	3	4	5	6	7	8	9	10	11	12
			•			•			•			•	
		Specimens: 3 plasma or serum samples, 0.5 mL.						Examinations: HSV IgG (qualitative/quantitative), HSV IgM, HSV-1 IgG, HSV-2 IgG.					

5680 HIV-1, nucleic acid detection (RNA)	3	1	2	3	4	5	6	7	8	9	10	11	12	
				●		●				●		●		
Specimens: 3 lyophilised plasma samples, 1.5 mL.		Examinations: HIV-1 RNA, quantitative and/or qualitative nucleic acid detection.												

	1	2	3	4	5	6	7	8	9	10	11	12	
5091 HIV, antibodies and antigen detection	3		●			●			●			●	
Specimens: 3 plasma or serum samples, 0.7 mL.													
Examinations: HIVAb (1/2), HIVAgAb (combo), HIVAg (p24), HIVAb confirmatory test and post-analytical clinical interpretation. Positive specimens may include HIV-1 or HIV-2.													

EQA³

		1	2	3	4	5	6	7	8	9	10	11	12
5088	HIV, antibodies and antigen detection, extra set of samples		●			●			●			●	
Specimens: 3 plasma or serum samples, 0.7 mL.		Notes: Only in connection with scheme 5091.											

												1	2	3	4	5	6	7	8	9	10	11	12	POCT	
5090 HIV, antibodies and antigen detection, POCT												3		●				●					●		
Specimens: 3 plasma or serum samples, 0.5 mL.												Notes: This scheme is only for POC tests. Scheme 5091 is for clinical laboratories.													
Examinations: HIVAb and HIVAgAb (combo) POCT.																									

												1	2	3	4	5	6	7	8	9	10	11	12	NEW
6801 HPV-related head and neck cancer control: HPV-NAT												③												
<p>Specimens: 2 cell-derived samples each including paraffin scrolls in a vial for NAT.</p> <p>Examinations: Scrolls: HPV nucleic acid detection.</p>												<p>Notes: HPV NAT to be performed on paraffin scrolls. Please see full product 6800 in the Oncology section.</p>												

		1	2	3	4	5	6	7	8	9	10	11	12
5556	HSV1&2/VZV/ <i>Treponema pallidum</i> , nucleic acid detection	3			●						●		
Specimens: 3 samples simulating swab samples taken from lesions. Examinations: Nucleic acid detection of HSV1, HSV2, VZV, <i>Treponema pallidum</i> . Notes: The samples contain hDNA.													

5086 Human papillomavirus, nucleic acid detection												3	1	2	3	4	5	6	7	8	9	10	11	12		
													•				•				•			•		
Specimens: 2 simulated samples, 1 mL.																										
Examinations: High-risk human papillomavirus NAT (hrHPVNAT). HPV genotypes included are: 16, 18, 31, 33, 39, 45, 51, 52, 66, 67.													Notes: Suitable for nucleic acid methods used in cervical cancer screening. The samples contain hDNA.													

	1	2	3	4	5	6	7	8	9	10	11	12	
5089 Human T-cell lymphotropic virus, antibodies	3		•		•			•			•		EQA³
Specimens: 3 plasma or serum samples, 0.5 mL.													
Examinations: HTLVAb screening and confirmatory tests, post-analytical clinical interpretation. Positive samples may include HTLV-1 or HTLV-2.													

	1	2	3	4	5	6	7	8	9	10	11	12
5670 Influenza virus A+B and RS virus, nucleic acid detection		•									•	
<div>3</div> <div>Specimens: 3 simulated samples, 1 mL. Examinations: InfANAT, InfBNAT, RSVNAT.</div> <div>Notes: See also scheme 5300 Respiratory infections multiplex, nucleic acid detection or 5562 Multiple respiratory virus, nucleic acid detection. The samples contain hDNA.</div>												

	1	2	3	4	5	6	7	8	9	10	11	12	
5671 Influenza virus A+B, antigen detection	3		●								●		POCT
<p>Specimens: 3 simulated samples.</p> <p>Examinations: InfAAG, InfBAg.</p> <p>Notes: For clinical laboratories and POCT sites. This scheme is only for antigen detection methods.</p>													

													1	2	3	4	5	6	7	8	9	10	11	12	
5668 Measles virus, antibodies													3	•			•			•			•		
Specimens: 3 plasma or serum samples, 0.5 mL.													Examinations: Measles virus IgG and IgM antibodies and post-analytical clinical interpretation.												

EQA³

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

	1	2	3	4	5	6	7	8	9	10	11	12	
5667 Rubella virus, antibodies	•			•			•			•			EQA³
Specimens: 3 plasma or serum samples, 0.5 mL.													
Examinations: Rubella virus IgG and IgM antibodies, IgG avidity and postanalytical clinical interpretation.													

	1	2	3	4	5	6	7	8	9	10	11	12	
5681 SARS-CoV-2, antigen detection	•			•			•			•			POCT
Specimens: 3 simulated samples.													
Examinations: SARS-CoV-2 Ag.													

	1	2	3	4	5	6	7	8	9	10	11	12	
5676 SARS-CoV-2, nucleic acid detection	•			•			•			•			POCT
Specimens: 3 simulated samples.													
Examinations: SARS-CoV-2 NAT.													

	1	2	3	4	5	6	7	8	9	10	11	12	
5099 Tick-borne encephalitis virus, antibodies			•			•			•			•	POCT EQA³
Specimens: 3 plasma or serum samples, 0.5 mL.													
Examinations: TBE IgG, IgM, total antibodies and post-analytical clinical interpretation.													

	1	2	3	4	5	6	7	8	9	10	11	12	
5665 Varicella-zoster virus, antibodies		•			•			•			•		EQA³
Specimens: 3 plasma or serum samples, 0.5 mL.													
Examinations: Varicella zoster IgG, IgM, total antibodies and post-analytical clinical interpretation.													

	1	2	3	4	5	6	7	8	9	10	11	12	
5688 West Nile virus, antibodies		•			•			•		•			NEW
Specimens: 2 plasma or serum samples, 0.5 mL.													
Examinations: West Nile Virus IgG, IgM and total antibodies.													

EQA schemes including Antimicrobial Susceptibility Testing

Bacteriology and mycology

5100	Blood culture
5190	Faecal culture (rounds 2 and 4)
5260	Fungal culture
5080	General Bacteriology 1
5081	General Bacteriology 2
5253	<i>Helicobacter pylori</i> , drug resistance, nucleic acid detection
5230	<i>Mycobacterium tuberculosis</i> , drug resistance, nucleic acid detection

5254	<i>Mycoplasma genitalium</i> , drug resistance, nucleic acid detection
5120	<i>Neisseria gonorrhoeae</i> (Gc), culture and susceptibility testing
5073	Surveillance for multidrug resistant bacteria, gramnegative rods
5071	Surveillance for multidrug resistant bacteria, MRSA
5072	Surveillance for multidrug resistant bacteria, VRE
5065	Urine culture, quantitative screening, identification and susceptibility

EQA schemes suitable for direct nucleic acid testing methods

Bacteriology

5241	<i>Bordetella pertussis/parapertussis</i> , nucleic acid detection
5612	<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> , nucleic acid detection
5201	<i>Clostridioides difficile</i> , nucleic acid detection
5191	Faecal bacterial pathogens multiplex, nucleic acid detection
5253	<i>Helicobacter pylori</i> , drug resistance, nucleic acid detection
5221	Mycobacterial nucleic acid detection
5230	<i>Mycobacterium tuberculosis</i> , drug resistance, nucleic acid detection
5254	<i>Mycoplasma genitalium</i> , drug resistance, nucleic acid detection
5599	<i>Streptococcus agalactiae</i> (GBS), nucleic acid detection
5595	<i>Streptococcus pyogenes</i> (Group A), detection in pharyngeal sample
5071	Surveillance for multidrug resistant bacteria, MRSA
5072	Surveillance for multidrug resistant bacteria, VRE
5073	Surveillance for multidrug resistant bacteria, gramnegative rods

Mycology

5261	Fungal infections, nucleic acid detection
------	-------------------------------------------

Parasitology

5472	Faecal parasites multiplex, nucleic acid detection
5430	Malaria, antigen and nucleic acid detection
5473	<i>Trichomonas vaginalis</i> , detection

Virology

5651	CMV and EBV, nucleic acid detection, quantitative
5689	HCV RNA from capillary blood, POCT
5679	Hepatitis B virus, nucleic acid detection (DNA)
5678	Hepatitis C virus, nucleic acid detection (RNA)
5680	HIV-1, nucleic acid detection (RNA)
5556	HSV1&2/VZV/ <i>Treponema pallidum</i> , nucleic acid detection
5086	Human papillomavirus, nucleic acid detection
5670	Influenza virus A+B and RS virus, nucleic acid detection
5562	Multiple Respiratory Virus, nucleic acid detection
5683	Mpox, nucleic acid detection
5675	Norovirus, nucleic acid detection
5676	SARS-CoV-2, nucleic acid detection

Multiplex

5191	Faecal bacterial pathogens multiplex, nucleic acid detection
5472	Faecal parasites multiplex, nucleic acid detection
5304	Gastrointestinal viral multiplex, nucleic acid detection
5303	Meningitis-encephalitis multiplex, nucleic acid detection
5300	Respiratory infections multiplex, nucleic acid detection
5302	Sexually transmitted diseases multiplex, nucleic acid detection
5305	Bacterial vaginosis and vaginitis multiplex, nucleic acid detection

LABQUALITY



**We are
Quality Makers**